BioCentury
ARTICLE | Clinical News

Esperion's bempedoic acid combo meets in Phase II for hypercholesterolemia

August 11, 2017 4:08 PM UTC

Esperion Therapeutics Inc. (NASDAQ:ESPR) reported top-line data from the Phase II 1002-038 trial in 63 patients with hypercholesterolemia showing that the once-daily combination of 180 mg bempedoic acid (ETC-1002)/10 mg Zetia ezetimibe plus 20 mg Lipitor atorvastatin met the primary endpoint of reducing LDL-C from baseline to week 6 vs. placebo (64% vs. 3%, p<0.001).

The combination plus atorvastatin also met the secondary endpoint of reducing median high-sensitivity C-reactive protein (hsCRP) levels from baseline to week 6 vs. placebo (48% vs. 3%, p<0.001). Additionally, a significantly greater proportion of patients receiving the combination plus atorvastatin achieved an LDL-C reduction of ≥50% (95% vs. 0%, p<0.001) and an LDL-C of <70 mg/dL (90% vs. 0%, p<0.001) vs. placebo. Esperion said the bempedoic acid/ezetimibe combination "complemented" the LDL-C lowering and hsCRP reductions seen with 20 mg atorvastatin...